LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
June 02, 2023 12:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced today that it will effect a 1-for-10 reverse stock split of its...
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
May 30, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 ...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
April 24, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
April 04, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal...
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
February 14, 2023 13:50 ET
|
Lixte Biotechnology Holdings, Inc.
THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM ...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
February 07, 2023 12:16 ET
|
Lixte Biotechnology Holdings, Inc.
--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
October 13, 2022 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and...
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
June 21, 2022 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies,...
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
June 15, 2022 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE...
LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market
April 14, 2022 18:45 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...